MTG had bought a 75% stake in Trace in 2014 in a deal that valued the media network operator at $54.4m.

Celgene has agreed to acquire Impact Biomedicines for a multibillion dollar whose total size may reach $7bn, giving an exit to fellow pharmaceutical company Sanofi. This is a record-setting deal in the life-sciences exits involving corporate investors, where other transactions like IPOs seems to have been in decline.

Mercari, whose corporate backers include Mitsui, Itochu, United and GMO, has set its sights on a Tokyo initial public offering that would value it at more than $1.8bn.

Via Oncology has been acquired by Elsevier for an undisclosed amount, nine years after being spun out of UPMC.

BCD Group has exited parking space booking platform Parkmobile through an acquisition by another corporate investor, BMW.

The corporate-backed cancer drug developer is reportedly valued at $1bn and is eyeing an initial public offering that could raise up to $200m.

The CapitalG-backed online polling platform, valued at $2bn as of 2014, is reportedly in talks with banks for an offering later this year.

The purchase data platform, which has raised more than $200m in financing, is backed by investors including Aimia and Fidelity Information Services.

Amazon Alexa Fund and GV have exited wifi router developer Luma, which had raised $22m, in an acquisition reportedly sized at more than $10m.